
Customer Validation
- •Cancer Res. 2016 Nov 15;76(22):6631-6642.
- •J Autoimmun. 2017 Jun;80:28-38.
- •Brain Behav Immun. 2017 Jan;59:322-332.
- •Basic Res Cardiol. 2017 Jan;112(1):9.
- •Oncotarget. 2017 May 9;8(19):31802-31814.
- •Oncotarget. 2017 May 2;8(18):29996-30007.
- •Oncotarget. 2017 Mar 28;8(13):21044-21053.
- •Cell Physiol Biochem. 2017 Mar 29;41(4):1675-1683.
- •Sci Rep. 2017 Mar 8;7:43834.
- •Sci Rep. 2017 Mar 8;7:43796.
- •Sci Rep. 2016 Aug 4;6:30957.
- •Sci Rep. 2016 Jun 9;6:27866.
- •J Neurochem. 2017 Oct;143(2):225-235.
- •J Neurochem. 2016 May;137(4):576-88.
- •Exp Cell Res. 2015 Feb 15;331(2):320-30.
- •Mol Pain. 2014 Feb 6;10(1):10.
- •Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1091-G1104.
- •Am J Physiol Gastrointest Liver Physiol. 2014 Feb;306(3):G244-52.
- •Neuroscience. 2017 Sep 30;360:128-138.
- •Food Funct. 2017 May 24;8(5):1905-1914.
- •Vaccine. 2017 Feb 15;35(7):1037-1045.
- •Vaccine. 2015 Apr 15;33(16):1923-33.
- •Life Sci. 2017 Feb 1;170:25-32.
- •Molecules. 2017 Jul 15;22(7). pii: E1187.
- •PLoS One. 2017 Jul 24;12(7):e0181796.
- •PLoS One. 2017 May 24;12(5):e0178147.
- •Oncol Rep. 2017 Jun;37(6):3341-3350.
- •Vet Microbiol. 2017 May;203:158-166.
- •J Sci Food Agric. 2017 Nov;97(14):4727-4736.
- •Photochem Photobiol. 2016 Nov;92(6):816-825.
- •J Biochem. 2017 Oct 18.
- •Cytotechnology. 2017 Apr;69(2):229-244.
- •BMC Musculoskelet Disord. 2014 Jan 15;15(1):18.
- •Mol Med Rep. 2017 Sep;16(3):3111-3116.
- •Oncol Lett. 2016 Aug;12(2):1034-1040.
- •Biosci Biotechnol Biochem. 2016 Jul;80(7):1393-402.
- •Chin Med J (Engl). 2017 Apr 20;130(8):906-913.
- •University of Arizona. 02-Nov-2017.
- •Biochem Biophys Rep. 2017 Sep;11:147-153.
- •Hainan Med J, Aug. 2017, Vol. 28, No. 15.
- •Chinese Journal of Public Health. 2016, 32(11): 1480-1484.
- •Universität Würzburg. 2016.
- •Seitoku University. 2014.
Description |
TAK-242 is a potent TLR4 signaling inhibitor, selectively inhibits the TLR4-mediated production of cytokines and NO. |
---|---|
IC50 & Target |
TLR4[1] |
In Vitro |
In RAW264.7 cells and mouse peritoneal macrophages, TAK-242 suppresses lipopolysaccharide (LPS)-induced production of NO, tumor necrosis factor-α (TNF-α), and interleukin (IL)-6, with IC50 of 1.1 to 11 nM. TAK-242 also suppresses the production of these cytokines from LPS-stimulated human peripheral blood mononuclear cells (PBMCs) at IC50 values from 11 to 33 nM[1]. |
In Vivo |
TAK-242 apparently reduces the serum anti-dsDNA levels in both genotype mice. Alternatively, IFN-γ, TNF-α, and IL-1β production is markedly inhibited by TAK-242, but their concentrations are still greatly higher than those in NS-treated counterparts[2]. TAK-242 pre-stress administration prevents the accumulation of potentially deleterious inflammatory and oxidative/nitrosative mediators in the brain frontal cortex of rats. TAK-242 i.v. administration at the beginning of the stress session completely blocks TLR-4 mRNA and protein upregulation after stress exposure[3]. |
Clinical Trial |
View MoreCollapse
|
References |
|
Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cell Assay
[1] |
TAK-242 is dissolved in N,N-dimethylformamide, and then diluted with appropriate medium before use[1]. RAW264.7 cells are seeded at a density of 3×106 cells/well in six-well culture plate and incubated overnight. After washing with RPMI 1640 medium supplemented with 1% FCS and 10 μg/mL Kanamycin, the cells are stimulated with 5 ng/mL LPS and 1 U/mL IFN-γ in the presence or absence of TAK-242 (1-100 nM) for the indicated time. Culture supernatants are removed, and total RNA is isolated using the total RNA isolation reagent ISOGEN. Total RNA is reverse transcribed into cDNA by using TaqMan reverse transcription reagents. Quantitative real-time PCR analysis of TNF-α and IL-6 is performed on ABI Prism 7700 using predeveloped TaqMan assay reagents and Universal PCR master mix. Quantitation of mRNA is performed using the comparative threshold cycle method. The highest control level attained by the stimulation (without TAK-242) is regarded as 100%, and the levels of control group at other time points and TAK-242-added group are expressed as the percentage of the highest control level[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Animal Administration
[2][3] |
TAK-242 is dissolved in vehicle (saline) (Mice)[2].
Mice[2] |
||||||||||||||||
References |
|
Molecular Weight |
361.82 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula |
C₁₅H₁₇ClFNO₄S |
||||||||||||
CAS No. |
243984-11-4 |
||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
Solvent & Solubility |
DMSO: ≥ 360 mg/mL TAK-242 is dissolved in a fat emulsion (i.v. injection)[4]. * "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> |
||||||||||||
References |
|
Purity: 99.95% ee.: 98.00%
COA (97 KB) HNMR (266 KB) RP-HPLC (236 KB) NP-HPLC (236 KB)
Handling Instructions (1252 KB)-
[1]. Ii M, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.
[2]. Ni JQ, et al. Role of toll-like receptor 4 on lupus lung injury and atherosclerosis in LPS-challenge ApoE⁻/⁻ mice. Clin Dev Immunol. 2013;2013:476856.
[3]. Gárate I, et al. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation. 2014 Jan 11;11:8.
[4]. Wang L, et al. Doxorubicin-Induced Systemic Inflammation Is Driven by Upregulation of Toll-Like Receptor TLR4 and Endotoxin Leakage. Cancer Res. 2016 Nov 15;76(22):6631-6642.
[5]. Shibata A, et al. Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA. J Autoimmun. 2017 Jun;80:28-38.
[6]. Janda J, et al. Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem Photobiol. 2016 Nov;92(6):816-825.
[7]. RAO Xiao-jiao, et al. Effect of TLR4 on expression of inflammatory cytokine in aortic artery in mice with insulin resistance[J]. Chinese Journal of Public Health, 2016, 32(11): 1480-1484.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
求助各位大神,现在想购买小分子数据库,求大神推荐。
我知道的免费的数据库有zinc
求推荐哪家公司或者研究所的小分子数据库可以购买,十分感谢!!!!!!
就是蛋白质分子的小片断
是氨基酸形成的
westblot蛋白免疫印迹实验跑小分子蛋白(15kd)条带一直是波浪状,有人说是胶的问题,可同时跑了36kd蛋白,条带是直的,有人说是要恒流跑,电压不要太大,我的转膜条件是50v,50min,请教各位大神指点,万分感谢!!!
有机的是有机化合物的简称,它指的是含碳化合物.
但是,有四大类常见物质一般不作为有机物处理:
1、碳的氧化物,如CO和CO2.
2、碳酸及其盐,如CaCO3.
3、金属碳化物,如CaC2.
4、拟卤素及其化合物,如(CN)2与KSCN.
水的化学式为H2O,它不含有碳元素,故不是有机物.
但若所描述的水不是化学意义的水,而是自然界存在的天然水,那么,水中会溶有一定量的有机物.
2017年4月26日|Filedunder:制药工业,制药企业,孤儿药,新药研发,制药常识,文献综合|Postedby:路人丙
【新闻事件】:在日前正在举行的美国神经学年会上MitsubishiTanabe公布了其ALS药物Edaravone的一个三期临床试验结果。在标准疗法基础上加入Edaravone显著改善ALS患者综合功能指标ALSFRS-R(-5.0对-7.5),同时也改善运动、呼吸等局部功能。Edaravone已经在韩国日本批准用于ALS,去年10月申请在美国上市,今年6月之前有望批准。
【药源解析】:ALS全称叫“肌肉萎缩性侧面硬化病”,也称LouGehrig氏病,因为30年代美国纽约洋基棒球队著名选手LouGehrig死于这个病。2014年风行一时的冰桶挑战让更多人知道了ALS,但ALS新药发现依然缓慢。美国目前只有riluzole这一个上市药物,能增加~10%的一年生存机会。
ALS的发病机理未知,动物模型十分不可靠,所以这个病的新药开发很难。过去10年大约只有十几个药物进入临床,基本全军覆没。走的最远的是百建艾迪的dexpramipexole,2013年初在三期临床失败。Edaravone号称是游离基清除剂,但分子机理未知。Edaravone最早作为中风药物开发,后来扩展到ALS。第一个三期临床失败,今天公布的是症状较轻患者。这个临床是日本人群,Edaravone并没有在美国IND和开展临床试验,所以如果批准将是比较特殊的情况(和Marathon的DMD药物Emflaza情况类似)。
Edaravone的另一个特殊性质是其分子结构。这个化合物分子十分简单,分子量只有174,可以算作是超小分子药物。现在有几十个分子量小于200的FDA批准药物,这类药物因为官能团数目有限不大可能与任何靶点有较高结合能,所以通常靶点未知。靶点未知又没有可靠动物模型,这类药物发现就更加困难。当然动物模型预测性差不是超小分子药物才面临的难题,多数神经系统药物、甚至现在最火热的肿瘤免疫疗法也面临同样问题。
这种临床前缺乏可靠评价体系的药物可以算是有D无R,这要求厂家冒更大的临床风险。只有潜在回报较大如没有任何标准疗法的罕见病或真正颠覆性药物如免疫疗法才可以适当采用这个模式。这个模式扩大化对厂家的长期生存是个威胁,因为新药的未知因素已经很多、成功率已经很低。没有临床前适当去风险的机会主义不可持续。
转发分享
美中药源原创文章,转载注明出处并添加超链接,商业用途需经书面授权。
★更多深度解析访问《美中药源》~
https://www.yypharm.com/?p=10664

